Boston Scientific has completed enrolment in the EVOLVE II randomised, controlled clinical trial. The EVOLVE II trial is designed to further assess the safety and effectiveness of the Synergy coronary stent system.
US Food and Drug Administration (FDA) and Japanese regulatory approvals for the treatment of atherosclerotic coronary lesions have been obtained. The Synergy stent uses the everolimus drug and features an ultra-thin directional polymer coating that is absorbed by the body shortly after drug elution ends at three months.
“The Synergy stent is the most flexible, conformable and deliverable drug eluting stent I have ever deployed,” said Dean Kereiakes, The Christ Hospital Heart and Vascular Center, Cincinnati, USA, and principal investigator for the study. “I am very pleased that the EVOLVE II trial enrolled so quickly and I look forward to the study results for this innovative stent which was designed for optimal vessel healing.”
The EVOLVE II trial began in November 2012 and has now completed enrolment of 1,684 patients at 125 sites worldwide, including the USA, Canada, Europe, Australia, New Zealand, Japan and Singapore. Boston Scientific received CE mark approval for the Synergy stent system in October 2012.
The EVOLVE II clinical trial builds upon the EVOLVE study, which was a prospective, randomised, single-blind, first-in-human use study comparing the Synergy stent system to the PROMUS Element stent system, which uses a durable polymer coating. Two-year outcomes with the Synergy stent in EVOLVE were presented earlier this year at the EuroPCR scientific programme in Paris and showed low rates of target lesion revascularization (1.1%) and no stent thrombosis with the Synergy stent throughout two years.
Patients enrolled in the EVOLVE II trial will be followed for five years. The Synergy stent system is an investigational device in non-CE mark countries and is not available for sale in the USA and Japan.